AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceNamed GroupsHealth CareGeographicals
Leishmaniasis, VisceralLeishmaniasis, CutaneousLeishmaniasisLeishmaniasis, MucocutaneousAntiprotozoal AgentsLeishmaniaLeishmania infantumLeishmania braziliensisLeishmania donovaniPsychodidaeLeishmaniasis, Diffuse CutaneousMeglumineLeishmaniasis VaccinesAntimonyPhlebotomusAntimony Sodium GluconateLeishmania tropicaDog DiseasesLeishmania guyanensisLeishmania majorLeishmania mexicanaAntigens, ProtozoanAntibodies, ProtozoanInsect VectorsEndemic DiseasesDNA, ProtozoanOrganometallic CompoundsBrazilParomomycinPhosphorylcholineDNA, KinetoplastProtozoan VaccinesParasite LoadDogsSudanAmphotericin BDisease ReservoirsInsect ControlVenezuelaParasitologyPentamidineIndiaMice, Inbred BALB CProtozoan ProteinsColombiaArgentinaSkin UlcerDisease VectorsSerologic TestsSensitivity and SpecificitySkin TestsNepalPolymerase Chain ReactionZoonosesAgglutination TestsBoliviaPeruSkinInterferon-gammaBenzethoniumEnzyme-Linked Immunosorbent AssayPopulation DensityEuglenozoa InfectionsParasitic Sensitivity TestsTrypanocidal AgentsNeglected DiseasesPanamaGeography, MedicalImmunochromatographyHyraxesAfghanistanMesocricetusTunisiaRodentiaInterleukin-10SeasonsIntradermal TestsEthiopiaIranFluorescent Antibody Technique, IndirectMacrophagesMilitary FacilitiesEcuadorSpleenSurinameTh1 CellsAsymptomatic InfectionsInsect Bites and StingsImmunoglobulin GBangladeshTopography, MedicalAIDS-Related Opportunistic InfectionsEyelid DiseasesChagas DiseaseUSSRAminoquinolinesMediterranean RegionFrench GuianaTrypanosomiasisRhinophyma
VisceralKala-azarLeishmaniaMucocutaneous leishmaniasis2023MucosalForms of leishmaniasisInfectionAbstractForm of leishmaniasisAreas where leishmaniasisAmphotericinPrevent leishmaniasisCases of cutaneous leishmaniasis2019Cutaneous leishmaniasis treatmentEfficacySkin soresHumansEndemic areaSymptomsClinical manifestationsType of leishmaniasisSandfliesSodiumInfectiousMeglumine antimoniateDiseasesPatientsParasitesDiffuseParomomycinAntimonyParasitic disease foundInfectionsEast AfricaLesionsPentavalent antimonialsSystematic reviewMiltefosineDiagnosis and treatmentProtozoan parasiticTravelersCanineCentral and Sou
Visceral84
  • Another type is visceral leishmaniasis (also called kala-azar or dum-dum fever ). (medicinenet.com)
  • HIV -visceral leishmaniasis ( HIV -VL) co-infection has emerged in southern Europe and elsewhere. (medicinenet.com)
  • Only 19 cases of cutaneous leishmaniasis and 12 cases of visceral disease were diagnosed in this group. (aafp.org)
  • Some species cause visceral leishmaniasis, some cause cutaneous disease, and some cause both. (aafp.org)
  • Visceral leishmaniasis is a systemic infection characterized by fever, weight loss, and hepatosplenomegaly, and it is usually fatal without treatment. (aafp.org)
  • The disease can present in three main ways as: cutaneous leishmaniasis, mucocutaneous leishmaniasis and visceral leishmaniasis. (disabled-world.com)
  • For visceral leishmaniasis, estimates of the number of instances range from around 200,000 to 400,000. (disabled-world.com)
  • The other main form of the disease is visceral leishmaniasis, which affects several of a person's internal organs such as their liver, spleen and bone marrow. (disabled-world.com)
  • Visceral leishmaniasis may be life-threatening. (disabled-world.com)
  • Fabiana Alves, Head of Visceral Leishmaniasis Clinical Programme, and Charles Mowbray, Discovery Director, explain why we are working towards new generation treatments for leishmaniasis. (dndi.org)
  • First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. (cdc.gov)
  • Zoonotic visceral leishmaniasis is a life-threatening disease caused by the multiplication of the protozoan parasite Leishmania infantum in the phagocytes of the reticuloendothelial system. (cdc.gov)
  • Reemergence of zoonotic visceral leishmaniasis in Italy: human cases recorded from 1987 through 2001 by passive repots and active surveillance. (cdc.gov)
  • In the first half of the 20th century, visceral leishmaniasis was a typical infantile syndrome in Italy with high incidence in southern regions and islands. (cdc.gov)
  • Incidence of visceral leishmaniasis in these patients, however, has recently decreased after the introduction of highly active antiretroviral therapy therapy ( Figure 1 ) ( 5 ). (cdc.gov)
  • Since the 1940s through 1990, meglumine antimoniate has been the only first-line drug for visceral leishmaniasis treatment in Italy ( 6 ). (cdc.gov)
  • From 1991 through 1994, a total of 90 patients of all ages, representing one third of all immunocompetent visceral leishmaniasis case-patients reported in Italy during that period, were enrolled in clinical trials of liposomal amphotericin B (L-AmB), which led to a novel, safe, short course of visceral leishmaniasis treatment as an alternative to meglumine antimoniate ( 7 , 8 ). (cdc.gov)
  • Because no official policy exists for visceral leishmaniasis therapy in Italy (physicians can prescribe any registered drug under their own responsibility) and information on drug regimens used is not included in visceral leishmaniasis case reports, we aimed to assess whether changes have occurred, and to what extent, in first-line drug regimens adopted in Italy after lipid-associated AmB was introduced into clinical practice. (cdc.gov)
  • A retrospective analysis was performed on data collected at the Unit of Protozoology of Istituto Superiore di Sanità, Rome, the main reference center for visceral leishmaniasis surveillance in Italy. (cdc.gov)
  • Diagnosis of visceral leishmaniasis in patients with clinically suspected cases was routinely performed on serum and bone marrow aspirate samples sent by hospitals, mainly from pediatrics, internal medicine, and infectious diseases wards, from throughout the country. (cdc.gov)
  • If visceral leishmaniasis was confirmed, relevant information on patients was recorded, which included drug regimens used and posttherapy results. (cdc.gov)
  • Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. (unboundmedicine.com)
  • WHO staff member Dr Abdelaziz Alahlafi meets Faris Hasan following his treatment for visceral leishmaniasis. (who.int)
  • Following a bone marrow biopsy, hospital doctors diagnosed him as suffering from visceral leishmaniasis. (who.int)
  • Visceral leishmaniasis, also known as kala-azar, is caused by a parasite transmitted through the bite of infected female sandflies. (who.int)
  • Outbreaks of visceral leishmaniasis are often fuelled by complex emergencies, mass population movements, famine and malnutrition. (who.int)
  • The most effective way to treat people with visceral leishmaniasis is with injections of sodium stibogluconate. (who.int)
  • Visceral leishmaniasis. (ajtmh.org)
  • Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? (ajtmh.org)
  • Efficacy and safety of liposomal amphotericin B (Am-Bisome) for visceral leishmaniasis in endemic developing countries. (ajtmh.org)
  • Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. (ajtmh.org)
  • Miltefosine: great expectations against visceral leishmaniasis. (ajtmh.org)
  • Miltefosine: an oral drug for visceral leishmaniasis. (ajtmh.org)
  • Additionally, you can get visceral leishmaniasis through blood transfusion or needle sharing. (webmd.com)
  • It's estimated that around 700,000 to 1.2 million people develop cutaneous leishmanias every year, while less than 100,000 people develop visceral leishmaniasis. (webmd.com)
  • Symptoms depend on whether you have cutaneous, mucocutaneous, or visceral leishmaniasis. (webmd.com)
  • As with cutaneous leishmaniasis, some people with visceral leishmaniasis won't have symptoms. (webmd.com)
  • If untreated, visceral leishmaniasis can be fatal. (webmd.com)
  • Systemic, or visceral, leishmaniasis affects the entire body. (medlineplus.gov)
  • Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. (medlineplus.gov)
  • Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. (mpg.de)
  • Visceral Leishmaniasis, which can affect the liver and spleen, is the most severe type of this disease. (healthinternetwork.org)
  • The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high relapse rate, especially when the CD4 count is low. (dndi.org)
  • METHODS: A web search of combinations of free text and Mesh terms related to the economic evaluation of visceral leishmaniasis was conducted on scientific publication databases (Web of Science, Scopus, Medline via the Pubmed and Lilacs). (fiocruz.br)
  • CONCLUSIONS: This article showed that health economic evaluations on visceral leishmaniasis used a wide range of technologies and methods. (fiocruz.br)
  • Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). (ox.ac.uk)
  • Depending on the parasite (sub)species and the immune status of the host, leishmaniasis presents as cutaneous disease (CL, ~90% of cases, presentation ranges between localized single lesions, and diffuce or recurrent forms), mucocutaneous leishmaniasis (MCL, mainly in the "new world," inefficient prior treatment or untreated primary CL), and visceral leishmaniasis. (mhmedical.com)
  • Post-kala-azar dermal leishmaniasis follows the treatment of visceral leishmaniasis and has predominantly been described in Africa (about 2% of cases) and India (about 10% of cases). (medscape.com)
  • The paper published in RSC Medicinal Chemistry tells another chapter in the story of the development of preclinical candidate DDD853651/GSK3186899 for the treatment of visceral leishmaniasis (VL), a disease caused by Leishmania parasites. (galchimia.com)
  • Visceral leishmaniasis or kala-azar ('black fever') is the most serious form, and is generally fatal if untreated. (wikipedia.org)
  • Leishmaniasis , an infectious disease , manifests itself mostly in two forms, cutaneous leishmaniasis (CL) and, a more severe and potentially deadly form, visceral leishmaniasis (VL). (bvsalud.org)
  • Leishmaniasis is a protozoan parasitic infection that, depending on the infecting species of Leishmania , can manifest in different forms, including cutaneous, mucocutaneous, or visceral leishmaniasis [ 1 ]. (e-epih.org)
  • C. Dye, The logic of visceral leishmaniasis control, Am. J. Trop. (sbmac.org.br)
  • The mass use of deltamethrin collars to control and prevent canine visceral leishmaniasis: A field effectiveness study in a highly endemic area, PLoS Negl Trop Dis (2018) 12(5): e0006496. (sbmac.org.br)
  • J.Moreno, Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis, Front. (sbmac.org.br)
  • A.P Seva, F. Ferreira, M. Amaku, How much does it cost to prevent and control visceral leishmaniasis in Brazil? (sbmac.org.br)
  • We retrospectively evaluated the rate of renal dysfunction during treatment with liposomal amphotericin B (L-AmB) (3-4 mg/kg, for 7-10 days) in nine consecutive patients with visceral leishmaniasis (VL). (edu.pl)
  • Clinical presentation and renal evaluation of human visceral leishmaniasis (kala-azar): a retrospective study of 57 patients in Brazil. (edu.pl)
  • Acute renal failure as initial presentation of visceral leishmaniasis in an HIV-1-infected patient. (edu.pl)
  • Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B. J Travel Med. (edu.pl)
  • Renal involvement in a patient with visceral leishmaniasis. (edu.pl)
  • 6] Navarro M, Bonet J, Bonal J, Romero R. Secondary amyloidosis with irreversible acute renal failure caused by visceral leishmaniasis in a patient with AIDS. (edu.pl)
  • Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil. (edu.pl)
  • This ecological study focused on the spatial pattern of visceral leishmaniasis cases in Brazil from 2007 to 2020 using data from the Information System for Notifiable Diseases (SINAN). (paho.org)
  • The variables analyzed were the incidence rate of visceral leishmaniasis and the visceral leishmaniasis composite indicator (VLCI), from which triennial thematic maps were constructed. (paho.org)
  • The global Moran index was calculated to assess the existence of spatial autocorrelation, and the local Moran index was used to identify areas with higher and lower risk of visceral leishmaniasis in Brazil. (paho.org)
  • During the study period, there were 48 705 cases of visceral leishmaniasis, with an incidence rate of 25.53 cases per 100 000 population. (paho.org)
  • The incidence of visceral leishmaniasis varied over the trienniums. (paho.org)
  • Immunopathogenesis of visceral leishmaniasis. (utmb.edu)
  • Results The barriers along the visceral leishmaniasis (VL) supply chain were identified as emerging themes, grouped across supply chain activities and health systems component(s). (bmj.com)
  • Relapses after treatment are more frequent than in visceral leishmaniasis. (karger.com)
  • HIV patients infected by Leishmania have frequently visceral involvement, and responses to treatment are poor. (karger.com)
  • Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects. (wikipedia.org)
  • A total dose of 21.0 - 30.0 mg/kg of body weight given over 10-21 days may be used in the treatment of visceral leishmaniasis. (medicines.org.uk)
  • A global clinical trial to establish the efficacy of a potential drug to treat visceral leishmaniasis (commonly known as Kala Azar in India) will be carried out predominantly in India in 2021 with additional trials in Africa. (thehindubusinessline.com)
  • The Pharma major Novartis and the Drugs for Neglected Diseases initiative (DND i ) , a not-for-profit research and development (R&D) organisation, headquartered in Geneva, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world's leading parasitic killers. (thehindubusinessline.com)
  • The DNDi, India has supported it by strengthening the capacity of five health care facilities in Bihar (Purnia, Saharsa, Saran, Vaishali and Mauzzafarpur District Hospitals) to conduct parasitological diagnosis of visceral leishmaniasis. (thehindubusinessline.com)
  • Existing treatments for visceral leishmaniasis are simply not good enough. (thehindubusinessline.com)
  • Visceral leishmaniasis causes irregular fever, hepatosplenomegaly, pancytopenia, and polyclonal hypergammaglobulinemia with high mortality in untreated patients. (msdmanuals.com)
  • Serologic testing can be helpful in diagnosing visceral but not cutaneous leishmaniasis. (msdmanuals.com)
  • Treatment of visceral leishmaniasis is with liposomal amphotericin B or miltefosine , depending on the infecting Leishmania species and the geographic area of acquisition. (msdmanuals.com)
  • Visceral leishmaniasis (kala-azar, Dumdum fever) is typically caused by L. donovani or L. infantum (previously called L. chagasi in Latin America) and occurs in India, Africa (particularly the Sudan), Central Asia, the Mediterranean basin, South and Central America, and infrequently China. (msdmanuals.com)
  • Adquirir conocimientos básicos sobre microbiología, patogenia y respuesta inmune de la leishmaniasis visceral para entender y apoyar el diagnóstico clínico, de laboratorio, tratamiento y seguimiento de los casos. (bvsalud.org)
  • But when people develop the disease, the most common forms are visceral leishmaniasis (also known as kala-azar), and then people would develop fever, they would lose weight, they would have an enlargement of the spleen and the liver. (cdc.gov)
Kala-azar2
Leishmania23
Mucocutaneous leishmaniasis8
20231
Mucosal6
Forms of leishmaniasis2
Infection8
  • Leishmaniasis is a 'vector-borne' infection, meaning that an insect from another host or 'reservoir' (disease carrier) transmits it. (medicinenet.com)
  • There are no drugs or vaccines available to prevent leishmaniasis infection. (disabled-world.com)
  • 1 billion people are at risk of infection with leishmaniasis, a neglected disease strongly linked to poverty. (dndi.org)
  • Epidemiological surveillance reveals that more than 350 million people in 98 countries are at potential risk of infection, which makes Leishmaniasis one of the six endemic diseases considered as high priorities worldwide [1]. (databasefootball.com)
  • Classified as a neglected tropical disease (NTD), leishmaniasis is an infection spread by phlebotomine sand flies. (webmd.com)
  • This infection is typically more common in rural areas, so be sure to take precautions as needed if you spend a lot of time outdoors in areas where leishmaniasis occurs. (webmd.com)
  • Active cutaneous leishmaniasis lesion with likely secondary infection in a soldier. (medscape.com)
  • Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity, Epidemiol. (sbmac.org.br)
Abstract1
  • ABSTRACT We assessed the effectiveness of photodynamic therapy in the treatment of cutaneous leishmaniasis in 5 patients. (who.int)
Form of leishmaniasis1
Areas where leishmaniasis2
  • In several geographic areas where leishmaniasis is found in people, infected people are not needed in order to maintain the transmission cycle of the parasite. (disabled-world.com)
  • People of all genders and ages are at risk if they go to areas where leishmaniasis occurs. (webmd.com)
Amphotericin3
Prevent leishmaniasis2
Cases of cutaneous leishmaniasis2
  • 5 Preliminary data on 22 cases of cutaneous leishmaniasis contracted by American troops in Afghanistan, Kuwait, and Iraq and treated at Walter Reed Army Medical Center between August 2002 and September 2003 were recently released. (aafp.org)
  • We conclude that this twice a day two-week regimen of aminosidine was inadequate to accelerate the recovery of most cases of cutaneous leishmaniasis. (ox.ac.uk)
20191
  • DDD853651/GSK3186899 was reported in 2019 as a drug candidate for the treatment of VL. (galchimia.com)
Cutaneous leishmaniasis treatment3
Efficacy6
  • In this paper we use a mathematical model to address the following question To what extent vaccine shots can enhance the efficacy of standard chemotherapy treatment of leishmaniasis ? (bvsalud.org)
  • Starting with standard MA treatment of leishmaniasis and combining it with three injections of V , we find, by Day 84, that efficacy increased from 29% to 65-91% depending on the amount of the vaccine . (bvsalud.org)
  • The aim of this study was to determine the efficacy of topical 5% imiquimod with cryotherapy vs. intralesional meglumine antimoniate (MA) in treatment of anthroponotic (dry type) CL. (iranjd.ir)
  • The objective of this study was to conduct a systematic review and meta-analysis of clinical trials that compared the efficacy of miltefosine and glucantime for the treatment of CL. (e-epih.org)
  • Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. (wikipedia.org)
  • Although doses greater than 5 mg/kg and up to a maximum of 10 mg/kg have been used in clinical trials and clinical practice, data on the safety and efficacy of AmBisome for the treatment of mucormycosis at these higher doses are limited. (medicines.org.uk)
Skin sores3
Humans3
Endemic area1
  • Conclusion: Although Meguimine antimoniate seems to be a more effective therapy for cutaneous leishmaniasis, this study revealed no significant difference in clinical response between combination of imiquimod and cryotherapy with intralesional MA in patients with cutaneous leishmaniasis in an endemic area of L. tropica. (iranjd.ir)
Symptoms5
  • Although several patients showed initial resolution of symptoms with imiquimod treatment alone, all of these patients experienced relapse after treatment discontinuation. (unboundmedicine.com)
  • To find out if you have leishmaniasis, you should ask yourself if you've been in a part of the world where leishmaniasis occurs and check if you have any of the symptoms covered above. (webmd.com)
  • Contact your provider if you have symptoms of leishmaniasis after visiting an area where the disease is known to occur. (medlineplus.gov)
  • Aloe vera gel, turmeric and other natural remedies can be used to reduce symptoms of leishmaniasis. (healthinternetwork.org)
  • Some suggest that treatment of Langerhans cell histiocytosis should be conservative and limited to individuals with constitutional symptoms, such as pain, fever, failure to thrive, and vital organ disorder as well as those with CNS risk involvement. (medscape.com)
Clinical manifestations2
  • The broad spectrum of clinical manifestations of cutaneous leishmaniasis often is compared with that of leprosy. (medscape.com)
  • A variety of topical and systemic treatments are available for cutaneous leishmaniasis depending on the causative species and clinical manifestations. (msdmanuals.com)
Type of leishmaniasis3
Sandflies5
Sodium5
  • The treatment mainstay is pentavalent antimony (e.g., sodium stibogluconate). (aafp.org)
  • Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. (ajtmh.org)
  • Varicella zoster virus meningitis complicating sodium stibogluconate treatment for cutaneous leishmaniasis. (ajtmh.org)
  • The current control strategy for leishmaniasis relies on chemotherapy drugs such as sodium antimony gluconate (SAG) and meglumine antimoniate (MA). (bvsalud.org)
  • The There have been many developments in the drugs of choices are sodium stibogluconate use of light for the treatment of a wide varif and meglumine antimonite (both pentavaf ety of skin conditions from nonfmelanoma lent antimony derivatives). (who.int)
Infectious2
  • Consultation with the CDC and an infectious disease consultant can assist with the diagnosis and treatment of cases imported into the United States. (medicinenet.com)
  • Leishmaniasis is an infectious disease spread by the bite of the female sandfly. (medlineplus.gov)
Meglumine antimoniate3
  • In the present pilot study, we compared the use of imiquimod, an immunomodulatory molecule, to the use of meglumine antimoniate alone and in combination for the initial treatment of cutaneous leishmaniasis. (unboundmedicine.com)
  • Patients were randomly assigned to 1 of 3 treatment groups and received either imiquimod 7.5% cream administered topically every other day for 20 days, intravenous meglumine antimoniate administered at a dosage of 20 mg/kg per day every day for 20 days, or combination therapy with both intravenous meglumine antimoniate and imiquimod 7.5% cream. (unboundmedicine.com)
  • Combination therapy with imiquimod and meglumine antimoniate is a promising regimen for the initial treatment of cutaneous leishmaniasis that warrants additional larger studies. (unboundmedicine.com)
Diseases7
  • Leishmaniasis is on the World Health Organization's list of 'neglected tropical diseases. (medicinenet.com)
  • Research, treatment, and eradication of diseases affecting very poor and resource-limited areas often require outside investment. (medicinenet.com)
  • WHO considers Leishmaniasis as one of the "Neglected Tropical Diseases" that continues to be prevalent despite international, national, and local efforts towards its control and elimination over the last decade. (intechopen.com)
  • Photodynamic therapy (PDT) involves the use of photochemical reactions mediated through the interaction of photosensitizing agents, light, and oxygen for the treatment of malignant or benign diseases. (medscape.com)
  • Objectives To understand stakeholders' perceptions of the access barriers to quality-assured diagnostics and medicines for leishmaniasis in the high-burden region of eastern Africa, and to identify key bottlenecks to improve the supply of commodities for neglected tropical diseases. (bmj.com)
  • In 2012 alone, well over 700 million preventive treatments were delivered to protect populations from the targeted neglected tropical diseases. (who.int)
  • A CDC scientist drafted the required FDA-documentation that allows the use of investigational drugs for patients with serious or immediately life-threatening diseases who lack other treatment options. (cdc.gov)
Patients14
  • International non-profit developing safe, effective, and affordable treatments for the most neglected patients. (dndi.org)
  • Patients with newly diagnosed cutaneous leishmaniasis were enrolled from a single referral center in Lima, Peru, from August 2005 through October 2005. (unboundmedicine.com)
  • Patients were evaluated weekly and at 1 and 3 months after treatment. (unboundmedicine.com)
  • In line, patients with known immunosuppression (which may lead to reactivation of the parasite) due to, eg, HIV, cancer, or anti-TNFa treatment, as well as all cases with MCL and VL should receive systemic therapy. (mhmedical.com)
  • Patients' expectations from treatment are rarely considered in drug development for CL. (ox.ac.uk)
  • This manuscript presents patient-preferred outcomes for CL and an assessment on how to consider these in the conduct of future trials.Methodology/principal findingsWe report preferred treatment outcomes by 74 patients with confirmed CL in endemic regions of Brazil, Burkina Faso, Colombia, Iran, Morocco, Peru and Tunisia during individual in-depth interviews. (ox.ac.uk)
  • The effect of a two-week regimen of topical aminosidine was investigated in a randomized, double-blind, placebo-controlled trial of 251 selected Iranian patients with zoonotic cutaneous leishmaniasis. (ox.ac.uk)
  • Patients underwent clinical and parasitologic assessment before and 15 (end of therapy), 45, and 105 days after starting the treatment. (ox.ac.uk)
  • During the first week of treatment, 5 patients (56%) experienced transient deterioration of renal function, with a rise in serum creatinine to 1.27-2.44 times the baseline level, and a parallel elevation of uric acid levels without other metabolic or electrolyte disturbances. (edu.pl)
  • This observation suggests that treatment of VL with intermittent L-AmB causes a subclinical tumor lysis-like syndrome, especially in patients with high parasite load. (edu.pl)
  • the empirical treatment of presumed fungal infections in febrile neutropenic patients, where the fever has failed to respond to broad spectrum antibiotics and appropriate investigations have failed to define a bacterial or viral cause. (medicines.org.uk)
  • Our hope is to radically transform this by developing new oral drugs that are affordable, safe, effective, easy to take, and can also be adapted to meet the treatment needs of patients in different countries," he said in a statement. (thehindubusinessline.com)
  • Improvements After 3-Year Ustekinumab or TNFi PsA Treatment Did these therapies lead to outcome and productivity improvements among psoriatic arthritis patients? (medscape.com)
  • A study by Duan et al indicated that in adult patients with either multisystem or multifocal single-system Langerhans cell histiocytosis, treatment with either vindesine and prednisone or cyclophosphamide, etoposide, vindesine, and prednisone was similarly effective. (medscape.com)
Parasites1
Diffuse4
Paromomycin1
Antimony3
Parasitic disease found2
  • Information regarding Leishmaniasis a parasitic disease found in parts of the tropics, subtropics and southern European regions. (disabled-world.com)
  • Leishmaniasis is a parasitic disease found largely in the tropics which the World Health Organisation has estimated infects 12 million people worldwide each year. (sciencedaily.com)
Infections5
  • In the same period, other lipid-associated AmB drugs were registered in Italy for the treatment of fungal infections, i.e. (cdc.gov)
  • The infections are chronic and may recur after treatment. (medscape.com)
  • The infections tend to be resistant to treatment. (medscape.com)
  • Over the next two years, CDC gathered evidence to justify treatment of FLA infections with miltefosine. (cdc.gov)
  • It is available for treatment of free-living ameba (FLA) infections caused by Naegleria fowleri, Balamuthia mandrillaris, and Acanthamoeba species. (cdc.gov)
East Africa2
  • Leishmaniasis occurs in several temperate and tropical countries of Central and South America (New World), the Middle East, East Africa, and East Asia (Old World). (medicinenet.com)
  • Cutaneous leishmaniasis is most common in Central and South America, the Middle East, and North and East Africa. (medicinenet.com)
Lesions6
  • Skin lesions are the most prevalent form of cutaneous Leishmaniasis. (healthinternetwork.org)
  • The hallmark of cutaneous leishmaniasis is skin lesions, which can spontaneously heal in 2-10 months. (medscape.com)
  • Therapy of leishmaniasis ranges from local treatment of cutaneous lesions to systemic often toxic, therapy for disseminated CL, ML and VL. (degruyter.com)
  • Other important items in the choice of treatment were the number of lesions and lesion location. (ac.ir)
  • Cutaneous leishmaniasis causes painless chronic skin lesions ranging from nodules to large ulcers that can persist for months to years but eventually heal. (msdmanuals.com)
  • Other alternative treatments and 2 had 2 lesions. (who.int)
Pentavalent antimonials1
Systematic review1
  • This article provides a brief and updated systematic review on the epidemiology, diagnosis and treatment of this neglected disease. (degruyter.com)
Miltefosine1
  • Miltefosine is a drug used to treat leishmaniasis , a rare tropical parasitic disease [iii] . (cdc.gov)
Diagnosis and treatment3
Protozoan parasitic1
  • Leishmaniasis is a protozoan parasitic disease transmitted by the bite of a sand fly. (mhmedical.com)
Travelers3
  • In other regions, such as the United States and Europe, travelers from affected areas may have leishmaniasis. (medicinenet.com)
  • Physicians in the United States must be alert to the diagnosis of leishmaniasis in travelers returning from endemic areas. (aafp.org)
  • a number of the instances of cutaneous leishmaniasis in American civilian travelers have been acquired in common tourist destinations such as Costa Rica or other Latin American destinations. (disabled-world.com)
Canine3
  • A vaccine used to prevent dogs from contracting the deadly, parasitic disease canine leishmaniasis also can be used to treat currently infected dogs, providing a new avenue of treatment for millions of infected dogs globally. (crctc.org)
  • In this work, we formulate a model to assess the impact of vaccination, insecticide-impregnated collar use, and treatment on the control of canine leishmaniasis. (sbmac.org.br)
  • Canine Leishmaniasis: An Overview of the Current Status and Strategies for Control. (sbmac.org.br)
Central and Sou2
  • New World' (Western hemisphere) leishmaniasis occurs in tropical parts of Mexico and Central and South America. (medicinenet.com)
  • Celine Gossner] Leishmaniasis is a parasitic disease, and it's found in parts of Asia, Africa, Central and South America, Middle East, and also Southern Europe. (cdc.gov)